0

540694

ANG

img img img img
No Data Available

ANG Lifesciences India Limited Share Price Update

As of the latest trading session, ANG Lifesciences India Limited is trading at ₹27.4, down by ₹-1.03 or -3.62% from its previous close. The stock has moved between ₹27.11 and ₹28.69 today. Over the past year, the stock has delivered a return of 5.41%. In the last month, it has returned 25.57%.

Investment Returns

Over 1 Month 25.57% Over 3 Months 8.22% Over 6 Months -7.57% Over 1 Year 5.41%
demotext Smart Investing Starts here ! Trade Smart with Fast Execution & Zero Account Opening Fees Invest Now

ANG Lifesciences India Limited fundamentals


  • Market cap (Cr) [-]
  • P/E Ratio (TTM) [-]
  • Beta [-]
  • Book Value / share [-]
  • Return on equity [-]%
  • EPS (TTM) [-]
  • Dividend yield [-]%
  • Net profit/quarter (Cr) [-]
info icon alternate text
  • Market cap (Cr) 36.00
  • P/E Ratio (TTM) -4.78
  • Beta 0.37
  • Book Value / share 49.97
  • Return on equity -14.37%
  • EPS (TTM) 0.00
  • Dividend yield [-]%
  • Net profit/quarter (Cr) -4.24
info icon alternate text

ANG Lifesciences India Limited Financials

  • Key Results
  • Key Ratios
  • Balance sheet
  • Cash Flow
  • Competition
info-icon
Revenue
Net income
Particulars DEC 2025 (Values in Cr)
Revenue 18.30
Operating Expense 23.43
Net Profit -4.24
Net Profit Margin (%) -23.16
Earnings Per Share (EPS) -3.23
EBITDA -1.92
Effective Tax Rate (%) 14.85
Particulars SEP 2025 (Values in Cr)
Revenue 25.97
Operating Expense 26.80
Net Profit -0.80
Net Profit Margin (%) -3.08
Earnings Per Share (EPS) -0.60
EBITDA 2.42
Effective Tax Rate (%) -29.03
Particulars JUN 2025 (Values in Cr)
Revenue 24.53
Operating Expense 25.74
Net Profit -0.79
Net Profit Margin (%) -3.22
Earnings Per Share (EPS) -0.59
EBITDA 2.03
Effective Tax Rate (%) 23.30
Particulars MAR 2025 (Values in Cr)
Revenue 17.67
Operating Expense 21.37
Net Profit -1.94
Net Profit Margin (%) -10.97
Earnings Per Share (EPS) -1.50
EBITDA 0.38
Effective Tax Rate (%) 34.45
Particulars DEC 2024 (Values in Cr)
Revenue 23.91
Operating Expense 29.44
Net Profit -4.57
Net Profit Margin (%) -19.11
Earnings Per Share (EPS) -3.50
EBITDA -2.01
Effective Tax Rate (%) 17.98
Particulars MAR 2025 (Values in Cr)
Revenue 89.91
Operating Expense 105.28
Net Profit -10.34
Net Profit Margin (%) -11.50
Earnings Per Share (EPS) -7.86
EBITDA 0.62
Effective Tax Rate (%) 20.01
Particulars MAR 2024 (Values in Cr)
Revenue 131.37
Operating Expense 139.34
Net Profit -8.65
Net Profit Margin (%) -6.58
Earnings Per Share (EPS) -6.48
EBITDA 8.21
Effective Tax Rate (%) 2.48
Particulars MAR 2023 (Values in Cr)
Revenue 207.01
Operating Expense 214.76
Net Profit -0.66
Net Profit Margin (%) -0.31
Earnings Per Share (EPS) 0.04
EBITDA 20.91
Effective Tax Rate (%) 131.88
Particulars MAR 2022 (Values in Cr)
Revenue 348.67
Operating Expense 296.56
Net Profit 39.71
Net Profit Margin (%) 11.38
Earnings Per Share (EPS) 38.51
EBITDA 66.03
Effective Tax Rate (%) 25.16
Particulars MAR 2021 (Values in Cr)
Revenue 154.28
Operating Expense 145.16
Net Profit 7.25
Net Profit Margin (%) 4.69
Earnings Per Share (EPS) 12.63
EBITDA 15.68
Effective Tax Rate (%) 26.47
Particulars MAR 2025 (Values in Cr)
Book Value / Share 45.40
ROE % -17.70
ROCE % -4.41
Total Debt to Total Equity 1.11
EBITDA Margin 0.12
Particulars MAR 2024 (Values in Cr)
Book Value / Share 54.82
ROE % -10.56
ROCE % 1.43
Total Debt to Total Equity 0.88
EBITDA Margin 7.28
Particulars MAR 2023 (Values in Cr)
Book Value / Share 62.43
ROE % -0.21
ROCE % 8.31
Total Debt to Total Equity 0.87
EBITDA Margin 10.74
Particulars MAR 2022 (Values in Cr)
Book Value / Share 76.28
ROE % 48.13
ROCE % 35.05
Total Debt to Total Equity 0.92
EBITDA Margin 19.42
Particulars MAR 2025 (Values in Cr)
Book Value / Share 50.88
ROE % -14.37
ROCE % -3.80
Total Debt to Total Equity 0.90
EBITDA Margin 1.08
Particulars MAR 2024 (Values in Cr)
Book Value / Share 58.74
ROE % -8.72
ROCE % 1.71
Total Debt to Total Equity 0.71
EBITDA Margin 7.78
Particulars MAR 2023 (Values in Cr)
Book Value / Share 61.91
ROE % -0.46
ROCE % 7.81
Total Debt to Total Equity 0.69
EBITDA Margin 9.99
Particulars MAR 2022 (Values in Cr)
Book Value / Share 76.00
ROE % 63.62
ROCE % 49.10
Total Debt to Total Equity 0.83
EBITDA Margin 19.07
Particulars MAR 2021 (Values in Cr)
Book Value / Share 76.99
ROE % 19.10
ROCE % 19.05
Total Debt to Total Equity 0.83
EBITDA Margin 10.42
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 3.63
Total Assets 229.59
Total Liabilities 229.59
Total Equity 63.97
Share Outstanding 1
Price to Book Ratio 0.45
Return on Assets (%) -5.40
Return on Capital (%) -8.6
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 5.73
Total Assets 242.43
Total Liabilities 242.43
Total Equity 76.27
Share Outstanding 1
Price to Book Ratio 0.77
Return on Assets (%) -4.18
Return on Capital (%) -6.97
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 6.17
Total Assets 277.66
Total Liabilities 277.66
Total Equity 86.21
Share Outstanding 1
Price to Book Ratio 1.23
Return on Assets (%) -0.09
Return on Capital (%) -0.17
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 6.65
Total Assets 291.03
Total Liabilities 291.03
Total Equity 83.76
Share Outstanding 1
Price to Book Ratio 3.09
Return on Assets (%) 13.85
Return on Capital (%) 25.08
Particulars MAR 2025 (Values in Cr)
Cash & Short Term Investments 3.55
Total Assets 208.66
Total Liabilities 208.66
Total Equity 66.80
Share Outstanding 1
Price to Book Ratio 0.45
Return on Assets (%) -4.95
Return on Capital (%) -7.68
Particulars MAR 2024 (Values in Cr)
Cash & Short Term Investments 5.49
Total Assets 217.42
Total Liabilities 217.42
Total Equity 77.07
Share Outstanding 1
Price to Book Ratio 0.77
Return on Assets (%) -3.97
Return on Capital (%) -6.51
Particulars MAR 2023 (Values in Cr)
Cash & Short Term Investments 6.05
Total Assets 252.50
Total Liabilities 252.50
Total Equity 85.53
Share Outstanding 1
Price to Book Ratio 1.23
Return on Assets (%) -0.26
Return on Capital (%) -0.48
Particulars MAR 2022 (Values in Cr)
Cash & Short Term Investments 6.58
Total Assets 268.68
Total Liabilities 268.68
Total Equity 83.48
Share Outstanding 1
Price to Book Ratio 3.09
Return on Assets (%) 14.78
Return on Capital (%) 27.49
Particulars MAR 2021 (Values in Cr)
Cash & Short Term Investments 0.11
Total Assets 142.24
Total Liabilities 142.24
Total Equity 41.35
Share Outstanding 0
Price to Book Ratio 1.11
Return on Assets (%) 5.09
Return on Capital (%) 8.66
Particulars MAR 2025 (Values in Cr)
Net Income -15.70
Cash from Operations 3.97
Cash from Investing -1.58
Cash from Financing 1.68
Net change in Cash -0.16
Free Cash Flow 7.72
Particulars MAR 2024 (Values in Cr)
Net Income -10.71
Cash from Operations 3.91
Cash from Investing 19.89
Cash from Financing -10.40
Net change in Cash 0.00
Free Cash Flow 9.48
Particulars MAR 2023 (Values in Cr)
Net Income 2.62
Cash from Operations 29.83
Cash from Investing -9.32
Cash from Financing -17.07
Net change in Cash -0.02
Free Cash Flow 40.28
Particulars MAR 2022 (Values in Cr)
Net Income 53.50
Cash from Operations 25.24
Cash from Investing -44.40
Cash from Financing 19.92
Net change in Cash 0.23
Free Cash Flow 66.58
Particulars MAR 2025 (Values in Cr)
Net Income -12.93
Cash from Operations 1.89
Cash from Investing -1.62
Cash from Financing 3.91
Net change in Cash 0.00
Free Cash Flow 6.01
Particulars MAR 2024 (Values in Cr)
Net Income -8.86
Cash from Operations 0.26
Cash from Investing 20.01
Cash from Financing -7.00
Net change in Cash -0.11
Free Cash Flow 5.70
Particulars MAR 2023 (Values in Cr)
Net Income 2.06
Cash from Operations 29.36
Cash from Investing -9.34
Cash from Financing -16.74
Net change in Cash -0.08
Free Cash Flow 39.80
Particulars MAR 2022 (Values in Cr)
Net Income 53.06
Cash from Operations 27.97
Cash from Investing -42.50
Cash from Financing 15.28
Net change in Cash 0.17
Free Cash Flow 67.31
Particulars MAR 2021 (Values in Cr)
Net Income 9.86
Cash from Operations -10.55
Cash from Investing -7.78
Cash from Financing 18.80
Net change in Cash -0.16
Free Cash Flow -6.48
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 31.07 13.45 1.61 238.10 23.12 40.44
BLISS GVS PHARMA LTD. 267.45 25.57 2.49 2829.33 105.05 280.20
CIPLA LTD. 1365.25 23.19 3.35 110282.52 1165.55 1672.20
FERMENTA BIOTECH LTD. 301.30 10.02 2.26 886.76 252.15 399.00
Company Name Price P/E P/B Market Cap 52 Week Low 52 Week High
AMBALAL SARABHAI ENT L 31.07 29.88 4.33 238.10 23.12 40.44
AMRUTAJAN HEALTH LTD 548.10 27.41 4.63 1584.59 490.00 789.95
ASTRAZENECA PHARMA IND LT 8369.45 100.58 26.18 20923.63 7630.00 10653.05
BLISS GVS PHARMA LTD. 267.45 36.44 2.56 2829.33 105.05 280.20

ANG Lifesciences India Limited shareholding pattern

Holding
29.39%
70.6%
44.88%
Name Shares Category
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)
(%)

ANG Lifesciences India Limited Technicals Summary

  • EMA & SMA
  • Resistance and Support
  • Delivery and Volume
  • Beta
  • Price Change Analysis
27.54 -3.13 redarrow
red-green-graph indicator
9 Bearish
7 Bullish
  • 5 Days 29.00
  • 26 Days 26.90
  • 10 Days 28.90
  • 50 Days 25.80
  • 12 Days 28.70
  • 100 Days 26.10
  • 20 Days 27.60
  • 200 Days 28.30
27.89 PIVOT
First Support 27.04 First Resistance 29.28 Second Support 25.65 Second Resistance 30.13 Third Support 24.80 Third Resistance 31.52
RSI 55.42 ADX 26.09 MACD 1.74 Williams % R -54.75 Commodity Channel Index (CCI) 21.56
Date 2026-05-06 Week 8117.00 Same Day 1958.00 Month 5836.00
1 Year 0.38 3 Year 0.22
Over 1 Month
25.57% down
Over 1 Year
5.41% down
Over 3 Months
8.22% down
Over 3 Years
-29.62% down
Over 6 Months
-7.57% down
Over 5 Years
-11.57% down

ANG Lifesciences India Limited Corporate Actions

Dividend date Dividend amount Dividend type Record date Instrument type
02 Nov 2021 1.0 Interim 04 Nov 2021 Equity shares
Ex-Date Ex-Bonus Ratio
14 Jul 2022 13 Jul 2022 1:4
23 Sep 2021 22 Sep 2021 1:1

Top Gainers

Top Losers

ANG Lifesciences India Limited Share Price

ANG Lifesciences India Limited was originally incorporated as a Private Limited Company with the name 'ANG Lifesciences India Private Limited' on June 14, 2006. On conversion into Public Limited Company, the name was changed to ANG Lifesciences India Limited on March 02, 2010. The Company further converted into Private Limited Company and the name of the Company was changed to 'ANG Lifesciences India Private Limited' on September 22, 2010. Subsequently, on conversion into Public Limited Company, the name again changed to 'ANG Lifesciences India Limited' on May 18, 2016.

The Company is engaged in the business of manufacturing and marketing of finished pharmaceutical formulation in the form of Sterile Dry Powder Injection Vials. In 2008-09, the Company started its commercial production. In 2014-15, it commenced direct sale of medicines covering hospitals , Doctors through stockists.

The Company is ISO-9001:2008 certified, which manufacture its products in compliance with GMP requirements. Company has dedicated area, machinery, facilities and advanced equipment for manufacturing of Beta Lactum & Non Beta Lactum products as per GMP norms. The Company currently operates a strong manufacturing set-up consisting of 4 formulation plants situated at Baddi, Himachal Pradesh. Its diversified product range covers multiple dosage forms, including dry powder injections, tablets, hard gelatin capsules, liquid syrups, liquid injections (ampoules/vials), and pre-filled syringes (PFS).

In August, 2017, the Company came up with a Public Issue of 15,00,800 Equity Shares by raising money from public aggregating to Rs 12 Crore.

The Company acquired Mansa Printers & Publishers Limited in April, 2021 for backward integration in pharma packaging to optimize costs and ensure timely availability of packaging products.

Parent organization Indian Private
NSE symbol [-]
Founded 2006
stock
Trade stocks with ease

Sign-in to trade with your demat account, or set up a new demat account for free

Board Of Directors

Left Arrow
Right Arrow

Similar stocks

Left Arrow
Right Arrow

Frequently Asked Questions

What is the Current Share Price of ANG Lifesciences India Ltd?

Answer Field

ANG Lifesciences India Ltd share price is for NSE ₹ 0.00 & for BSE ₹ 27.54 as on May 07 2026 03:29 PM.

What is the Market Cap of ANG Lifesciences India Ltd Share?

Answer Field

The market cap of ANG Lifesciences India Ltd for NSE ₹ 0.00 & for BSE ₹ 36.00 as on May 07 2026 03:29 PM.

What is the 52 Week High and Low of ANG Lifesciences India Ltd?

Answer Field

The 52 Week High and Low of ANG Lifesciences India Ltd for NSE is ₹ 0.00 and ₹ 0.00 and for BSE is ₹ 39.70 and ₹ 17.63.

What is 1 year return for ANG Lifesciences India Ltd?

Answer Field

The 1 year returns on the stock has been 5.41%.

What is the P/E Ratio of ANG Lifesciences India Ltd Share?

Answer Field

As on May 07 2026 03:29 PM the price-to-earnings (PE) ratio for ANG Lifesciences India Ltd share is -4.78.

What is the PB ratio of ANG Lifesciences India Ltd Share?

Answer Field

As on May 07 2026 03:29 PM, the price-to-book (PB) ratio for ANG Lifesciences India Ltd share is 49.97.

How to Buy ANG Lifesciences India Ltd Share?

Answer Field

You can trade in ANG Lifesciences India Ltd shares with Bajaj Broking by opening a demat account.

How to Buy ANG Lifesciences India Ltd Share on Bajaj Broking App?

Answer Field

To buy ANG Lifesciences India Ltd shares on the Bajaj Broking app, follow these steps:

• Login to the Bajaj Broking App

• Click on the Search Icon

• Search “ANG Lifesciences India Ltd”

• Click on the BUY icon

• Place a buy order specifying the desired quantity of shares.

• Click BUY again to complete the purchase

No results found

close-image

Get Free Demat Account*

+91
close-img

Authorise with OTP

Enter the 4-Digit OTP sent to
edit
OTP expires in 00:59
banner-icon

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|

Please Enter Mobile Number

Open Your Free Demat Account

Enjoy low brokerage on delivery trades

+91

|